Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-789 in TKI-resistant EGFR-mutated metastatic non-squamous NSCLC
2017-004188-11Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC), Non-small cell lung cancer (NS-NSCLC) and EGFR-mutated non-small cell lung cancer comparing Pembrolizumab + pemetrexed + platinum chemotherapy with Placebo + pemetrexed + platinum chemotherapy (2 arms). Primary endpoint: Progression-free survival. Started Mar 2018; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)Non-small cell lung cancer (NS-NSCLC)EGFR-mutated non-small cell lung cancer
Beyond the preview
Go deeper on 2017-004188-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004188-11.